Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$3.66
+1.8%		$3.80
$3.10
▼
$7.20
$7.04M1.0926,990 shs2,476 shs
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
$1.01
+3.6%		$1.00
$0.62
▼
$6.25
$6.62M2.043.48 million shs143,954 shs
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$3.58
-1.1%		$4.26
$3.18
▼
$71.50
$5.84M2.61738,425 shs10,296 shs
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
$0.26
-0.8%		$0.98
$0.24
▼
$42.60
$1.42M-0.361.72 million shs837,445 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-1.64%+7.16%-6.63%-16.12%-37.78%
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
-0.39%+10.54%-21.77%-19.17%-68.81%
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-0.82%-3.72%-26.57%-48.06%-87.19%
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
-18.49%-32.37%-29.59%-90.65%-99.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$3.66
+1.8%		$3.80
$3.10
▼
$7.20
$7.04M1.0926,990 shs2,476 shs
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
$1.01
+3.6%		$1.00
$0.62
▼
$6.25
$6.62M2.043.48 million shs143,954 shs
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$3.58
-1.1%		$4.26
$3.18
▼
$71.50
$5.84M2.61738,425 shs10,296 shs
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
$0.26
-0.8%		$0.98
$0.24
▼
$42.60
$1.42M-0.361.72 million shs837,445 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-1.64%+7.16%-6.63%-16.12%-37.78%
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
-0.39%+10.54%-21.77%-19.17%-68.81%
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-0.82%-3.72%-26.57%-48.06%-87.19%
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
-18.49%-32.37%-29.59%-90.65%-99.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
2.25
Hold$14.50296.72% Upside
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
2.00
HoldN/AN/A
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
2.00
Hold$30.00737.99% Upside
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest SLXN, BOLT, CELZ, and ERNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/11/2026
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/10/2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/27/2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/20/2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/13/2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/31/2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/29/2026
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/17/2026
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$4.70M1.50N/AN/A$13.81 per share0.26
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
$10K662.30N/AN/A$2.04 per share0.49
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$580K10.06N/AN/A$7.64 per share0.47
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/AN/AN/AN/A$8.33 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$33.38M-$16.44N/AN/AN/A-611.47%-126.23%-54.70%11/11/2026 (Estimated)
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
-$5.99M-$2.07N/AN/AN/AN/A-86.52%-81.96%11/6/2026 (Estimated)
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-$14.08M-$14.35N/AN/AN/AN/A-305.93%-169.86%11/6/2026 (Estimated)
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
-$11.91M-$42.47N/AN/AN/AN/A-563.11%-201.73%11/11/2026 (Estimated)

Latest SLXN, BOLT, CELZ, and ERNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/15/2026Q2 2026
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
-$21.20-$5.17+$16.03-$5.17N/AN/A
8/11/2026Q2 2026
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$3.39-$4.57-$1.18-$4.57$0.50 million$0.01 million
8/7/2026Q2 2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
-$0.39-$0.41-$0.02-$0.41N/AN/A
8/6/2026Q2 2026
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-$3.30-$3.40-$0.10-$3.40N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$0.369.85%N/AN/A N/A
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
N/AN/AN/AN/AN/A
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/AN/AN/AN/AN/A
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
1.47
2.61
2.61
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
N/A
12.90
12.90
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/A
2.01
2.01
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/A
0.94
0.94

Institutional Ownership

CompanyInstitutional Ownership
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
86.70%
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
1.42%
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
70.55%
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
10.95%

Insider Ownership

CompanyInsider Ownership
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
9.40%
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
1.00%
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
0.53%
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
0.77%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
231.93 million1.75 millionNot Optionable
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
46.59 million6.53 millionNot Optionable
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
51.63 million1.62 millionNo Data
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
145.56 million5.52 millionN/A

Recent News About These Companies

Equities Analysts Issue Forecasts for SLXN FY2026 Earnings
September 25 at 1:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31046842
Brokers Issue Forecasts for SLXN FY2027 Earnings
September 22 at 7:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31039645
5 Biotech Stocks In Spotlight: Tenon Medical, AEON Biopharma, Silexion, Orchestra BioMed & Indaptus
September 10, 2026  |  rttnews.comhttps://www.rttnews.com/3690118/5-biotech-stocks-in-spotlight-tenon-medical-aeon-biopharma-silexion-orchestra-biomed-indaptus.aspx
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3358748/0/en/silexion-therapeutics-to-participate-in-september-2026-industry-and-investor-conferences.html
Silexion Posts Wider Q2 Loss On Higher SIL-204 Development Costs
September 4, 2026  |  rttnews.comhttps://www.rttnews.com/3688621/silexion-posts-wider-q2-loss-on-higher-sil-204-development-costs.aspx
After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)
August 25, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/currencies/after-moderna-s-44b-oncology-win-silexion-s-pancreatic-cancer-treatment-is-worth-exploring-nasdaq-slxn-1036490067
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345339/0/en/silexion-therapeutics-reports-second-quarter-2026-financial-results-and-provides-business-update.html
Silexion Therapeutics Prices $2.5 Million Securities Offering; Shares Down Pre-Bell
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/silexion-therapeutics-prices-2-5-081643165.html
Silexion Therapeutics Prices $2.5 Million Public Offering of Ordinary Shares and Warrants
August 11, 2026  |  quiverquant.comQ
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
August 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/12/3343316/0/en/silexion-therapeutics-announces-pricing-of-2-5-million-public-offering.html
Immunotherapy's Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN)
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/currencies/immunotherapy-s-biggest-blind-spot-is-a-7-billion-market-silexion-may-have-a-way-in-nasdaq-slxn-1036437857
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers
August 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/silexion-therapeutics-reports-positive-preclinical-131500001.html
Silexion Therapeutics Reports Preclinical Data Showing SIL204 Immune-Sensitizing Effects in KRAS-Mutant Cancer Cells
August 4, 2026  |  quiverquant.comQ
Silexion Therapeutics Announces Board Member Resignation
July 31, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/silexion-therapeutics-announces-board-member-resignation?utm_source=marketbeat.com&utm_medium=referral
Silexion Therapeutics Initiates Phase 2/3 Trial for Pancreatic Cancer Drug Candidate
July 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/silexion-therapeutics-initiates-phase-2-134322002.html
Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)
July 29, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/currencies/silexion-activates-first-site-in-phase-2-3-trial-targeting-kras-driven-pancreatic-cancer-nasdaq-slxn-1036378280
Silexion Therapeutics initiates phase 2/3 trial of SIL204 in pancreatic cancer
July 29, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/silexion-therapeutics-initiates-phase-23-trial-of-sil204-in-pancreatic-cancer/ar-AA28ZxiD
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
July 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/29/3335106/0/en/silexion-therapeutics-successfully-initiates-phase-2-3-clinical-trial-of-sil204-in-locally-advanced-pancreatic-cancer-at-tel-aviv-sourasky-medical-center.html
Silexion Therapeutics
July 21, 2026  |  fool.comhttps://www.fool.com/quote/nasdaq/slxn/
Silexion Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:SLXN
July 1, 2026  |  benzinga.comhttps://www.benzinga.com/quote/SLXN/earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bolt Biotherapeutics stock logo

Bolt Biotherapeutics NASDAQ:BOLT

$3.66 +0.07 (+1.81%)
As of 12:37 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Creative Medical Technology stock logo

Creative Medical Technology NASDAQ:CELZ

$1.00 +0.04 (+3.61%)
As of 12:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Ernexa Therapeutics stock logo

Ernexa Therapeutics NASDAQ:ERNA

$3.58 -0.04 (-1.10%)
As of 12:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Silexion Therapeutics stock logo

Silexion Therapeutics NASDAQ:SLXN

$0.26 0.00 (-0.78%)
As of 12:58 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas